NEU 0.81% $12.25 neuren pharmaceuticals limited

ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-64

  1. 599 Posts.
    lightbulb Created with Sketch. 326
    Maybe we will understand better:


    December 2, 2022 - 4:30 pm
    Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ET

    NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company” (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that management will host a conference call on Monday December 5, 2022, at 8:30 am ET to review ANAVEX®2-73-AD-004 Alzheimer’s disease Phase 2b/3 study results.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$12.25
Change
-0.100(0.81%)
Mkt cap ! $1.565B
Open High Low Value Volume
$12.20 $12.25 $12.02 $3.677M 302.0K

Buyers (Bids)

No. Vol. Price($)
1 1579 $12.21
 

Sellers (Offers)

Price($) Vol. No.
$12.26 1199 1
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.